Xinlitai new drug R & D investment increased by 118%

Xinlitai (002294) released the 2015 financial report on March 22, and realized an annual operating revenue of 3.478 billion yuan, a year-on-year increase of 20.64%; the net profit attributable to the shareholders of the listed company was 1.266 billion yuan, a year-on-year increase of 21.45%; the R & D investment was 315 million yuan, accounting for 9.05% of the operating revenue, a year-on-year increase of 117.76% According to the financial report, xinlitai regards improving the acquisition ability of new products as a key content of its work in 2016, and arranges the general manager of the company to directly manage BD business, actively promote the phase I clinical research of bf27 (anti-CD20 monoclonal antibody), implement the introduction of new gene therapy products and other projects, and actively prepare for the biological innovation research institute to enhance innovation ability Also on March 22, xinlitai disclosed the strategic cooperation agreement on innovative drugs with Academician Wei Yuquan of Sichuan University The two sides will carry out industry university research cooperation on innovative drugs and establish a strategic cooperation relationship in the growth period, build a scientific research platform, jointly conduct scientific research experiments and promote the industrialization of scientific research achievements The main content of the cooperation is that the two sides plan to take the lead in carrying out clinical research on three innovative gene therapy projects in the biological laboratory of Sichuan University The above projects are applicable to the treatment of multiple tumors The company can give priority to the pilot test and industrial transformation of the innovation project of Sichuan University Biological Laboratory; both parties will jointly organize scientific research teams with research basis in the field of biotechnology and drugs to carry out research on relevant innovation topics Sichuan University biological laboratory assisted the company in the construction of "xinlitai Shenzhen Biomedical Innovation Research Institute" to select projects that can enter the pilot test and industrialization as project reserves for the company Relying on the Research Institute, both sides build a postdoctoral innovation base and set up enterprise postdoctoral workstation; Chuanda biology laboratory carries out order based talent training for the company to meet the company's demand for talents in technology research and development and enterprise management If the innovation project developed by Chuanda biological laboratory is in line with the company's development strategy, it can be given priority to the company for industrial implementation These three innovative gene therapy projects mainly include a new in situ tumor vaccine, an anti-tumor drug based on gene editing technology and a targeted gene therapy drug based on RNA interference technology for ovarian cancer Wei Yuquan, vice president of Sichuan University, said that the above-mentioned projects have carried out pharmaceutical, pharmacological and part of the pharmacodynamic experimental research, established a stable production process and quality standards, and will enter the clinical trial research in the next step Ye Yuxiang, general manager of xinlitai, said: "these three projects are all original innovative varieties, with independent intellectual property rights There are no similar products at home and abroad, which are suitable for the treatment of multiple tumors The first indication for development is ovarian cancer Compared with traditional chemotherapy drugs, gene therapy has significant advantages and safety, its tumor inhibition rate is relatively high, the individual tolerance is good, the survival rate is high, it is expected to be used as an alternative treatment of postoperative chemotherapy, or combined with first-line chemotherapy drugs, to improve the treatment effect Ye Yuxiang pointed out: "at the two sessions, the country is vigorously promoting strategic emerging industries The cooperation between xinlitai and Sichuan University is in line with the situation, and will vigorously develop innovative biomedical fields under the guidance of scientific research industrialization and marketization At present, China is very close to the world's most advanced level in the field of biomedicine, and innovative R & D of new drugs has the opportunity to become the world's best products " Research and development of xinlitai: in 2015, xinlitai set up 8 varieties, applied for registration of 6 varieties, and 26 projects were under research throughout the year In 2015, 36 new invention patents were applied for (including 3 PCT invention patent applications and 3 Taiwan invention patent applications); 8 invention patents (including 1 in Europe and 1 in the United States) and 5 utility model patents were authorized Currently, there are 89 valid patents and 74 are being applied for Fugliptin benzoate, an innovative drug with compound patent, has completed phase I clinical trials with ideal results, which is being accelerated; PTH (recombinant human parathyroid hormone 1-34) phase III clinical trials with ideal results will be applied for production in the second half of 2016; KGF (recombinant human keratinocyte growth factor) ）Bf02 is in phase II clinical stage and is expected to enter phase III clinical stage in 2016 Fully degradable coronary stent (BVS) has entered the clinical research stage.